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Endovascular stent graft for symptomatic mobile
thrombus of the thoracic aorta
Philipp Fueglistaler, MD, Thomas Wolff, MD, Lorenz Guerke, MD, Peter Stierli, MD, and
Thomas Eugster, MD, Basel, Switzerland
Mobile thoracic aortic thrombus is a potential source of arterial embolism. Therapeutic management remains controver-
sial. Systemic anticoagulation and various open surgical procedures are the commonly used therapeutic modalities. We
report the successful primary treatment by endovascular stent graft of a mobile thoracic aortic thrombus that had caused
visceral and peripheral embolism. Our case shows that endovascular stent-graft treatment is an effective, minimally
invasive treatment of symptomatic mobile thoracic aortic thrombus. (J Vasc Surg 2005;42:781-3.)Thoracic aortic thrombus is a rare pathology that usu-
ally originates from an atherosclerotic aortic wall lesion or
an aortic aneurysm and is a potential source of visceral,
cerebral, and peripheral embolism. The best therapeutic
approach remains controversial. Literature reports are
mainly of open surgical procedures. Minimally invasive
procedures may reduce perioperative morbidity and mor-
tality. We describe a case of mobile thoracic aortic throm-
bus, causing peripheral embolic occlusion, which was suc-
cessfully treated by using endovascular stent-graft (ESG)
exclusion as the primary therapeutic approach.
CASE REPORT
A 74-year-old woman with known hypertension,
smoking (30 pack-years), and obesity (body mass index,
28) was admitted with a history of recurrent abdominal
pain and diarrhea for 3 weeks and acute onset of paresthesia
of the right lower leg 1 week later. The abdomen was soft
and tender around the umbilicus, without audible bruits.
Right popliteal and pedal pulses were absent.
A computed tomography (CT) scan revealed an ap-
proximately 2-cm  1-cm endoluminal mass in the aortic
arch, 1.5-cm distal to the origin of the left subclavian artery
(Fig 1). Transthoracic echocardiography confirmed the
diagnosis of a mobile, mural aortic thrombus. No cardiac
pathologies were noted.
Thrombophilia due to a heterozygous prothrombin
mutation was found on screening for coagulation disorders.
Serum levels of creatinine (124 umol/L [normal, 45-93
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doi:10.1016/j.jvs.2005.05.054umol/L]) and C-reactive protein (265 mg/L [normal,
10mg/L]) were elevated. Liver function test results were
normal.
Endovascular treatment of the thrombus to prevent
further embolization was chosen and informed consent was
obtained. A cutdown of the right femoral artery was per-
formed. The initial angiogram demonstrated occlusion of
the right popliteal and proximal tibial arteries, an occluded
right hepatic artery, and peripheral filling defects of small
mesenteric arteries. A guidewire was placed in the aortic
arch under fluoroscopic control, with particular care to
avoid dislodging the thrombus (Fig 2).
Thrombus exclusion was performed by introducing a
37-mm  15-cm thoracic aortic stent graft (TAG, Gore-
Tex, W. L. Gore & Assoc, Flagstaff, Ariz). Balloon occlu-
sion of the aorta was not performed. The final angiogram
showed perfect stent-graft position distal to the origin of
the left subclavian artery (Fig 3). The luminal thrombus,
lodged between the stent graft and the aortic wall, could
not be visualized. Finally, embolectomy of the right popli-
teal artery was performed through the right femoral access.
In view of normal hepatic enzymes, the occluded right
hepatic artery was not treated.
The peripheral emboli in the mesenteric circulation,
which might explain the chronic abdominal pain that had
occurred in the weeks before, were too small to be amena-
ble to embolectomy. Since neither CT scan nor angiogram
revealed embolism of the renal arteries or any signs of renal
infarction, the increased creatinine was not thought to be
related to the aortic thrombus.
A postoperative CT scan confirmed exclusion of the
thrombus. Abdominal pain resolved several days after the
intervention. The patient was discharged with oral anticoag-
ulation, which will be maintained life-long in view of the
prothrombin mutation. Three months postoperatively, the
patient is doing well.
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Mobile thoracic aortic thrombus is a rare pathology,
with only some 100 cases published.1 Factors that may
cause aortic thrombi include aortic wall pathologies such as
atherosclerotic lesions, aneurysms, different forms of endo-
thelial arterial disorders, and hypercoagulability.2-4 In the
present case, serologic results revealed a heterozygous pro-
thrombin gene mutation in this overweight elderly smoker,
suggesting that the cause of thrombus formation was mul-
tifactorial. Commonly, aortic thrombus is only diagnosed
after clinical manifestation of embolic events. The inci-
dence of thoracic aortic thrombi in cases of peripheral
Fig 1. A computed tomography scan demonstrates the mobile
mural thrombus in the distal aortic arch.
Fig 2. An angiogram demonstrates the thrombus before place-
ment of the stent graft with and angiographic catheter and guide-
wire.embolism is reported to be as high as 9%.5In case of embolization from a thrombus, there is a risk
of recurrent embolization with potentially dire conse-
quences. Therapy should therefore be started immediately
to remove the thrombus as the source of embolization and
thereby reduce the risk of thrombus recurrence. There is as
yet no therapeutic standard for mobile thoracic aortic
thrombus. Only retrospective studies with limited patient
numbers and case reports have been published. A variety of
approaches are used, including conservative treatments
with anticoagulation1,6 or thrombolysis,7 interventional
modalities such as thromboaspiration5 or balloon-catheter
thrombectomy,8 and open surgical procedures2,3,5,9,10
such as thrombectomy, thromboendarterectomy, and aor-
tic prosthetic replacement. Exclusion by an ESG is a new
approach.11
Complete disappearance or reduction in the size of the
thrombus has been reported with the use of anticoagulation
alone.1,6 Choukroun et al1 suggest a strategy beginning with
anticoagulation, followed by surgical thrombus removal only
when anticoagulation alone is not effective. In contrast,
other investigators have recommended an aggressive surgi-
cal approach using aortic thromboendarterectomy.3 Goëf-
fic et al10 treated 38 patients by various open surgical
techniques. They reported a perioperative morbidity of
29% and a mortality of 2.6% and therefore recommend
open surgery only in case of recurrent embolic events.10
Minimally invasive thrombectomy has been performed
effectively using an aortic balloon catheter introduced via
the common femoral or iliac artery under transesophageal
echocardiographic guidance.8 Although minimally inva-
sive, this technique carries the risk of accidental visceral and
internal iliac artery embolization during aortic thrombus
mobilization. Furthermore, a small thrombus is presum-
ably remnant, and the residual atherosclerotic aortic wall
Fig 3. An angiogram demonstrates the stent graft implanted
directly distal to the origin of the left subclavian artery over a
guidewire and the disappearance of the endoluminal thrombus.lesion may promote recurrent thrombus development.
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moves the thrombus but also treats the underlying cause by
covering the atherosclerotic aortic wall. Although there are
no data comparing the thrombogenicity of an atheroscle-
rotic aortic wall lesion with the lumen of a covered stent
graft, experience from use of thoracic aortic stent grafts to
treat aneurysms suggests that thrombus generation in a
thoracic aortic stent graft with normal configuration and
high flow is extremely rare.
Another benefit of the ESG treatment is the possibility
of combining the thoracic procedure with a peripheral
embolectomy through the same surgical access. Shames et
al12 performed ESG thrombus exclusion in eight patients at
different locations outside the thoracic aorta (abdominal
aorta, iliac and subclavian arteries) with promising results.
They observed no apparent embolic events during ESG
implantation and there was no evidence of recurrent emboli
within a 12-month follow-up period, demonstrating the
safety and efficacy of ESG exclusion.
Up to now, Criado et al11 have published the only
report of ESG treatment of a thoracic aortic thrombus.
They describe a case of thrombus recurrence after open
surgical thrombectomy and systemic anticoagulation.11 In
contrast, in the present case, we used an ESG as the primary
treatment.
Admittedly, introducing the guidewire and stent graft
carries a certain risk of dislodging the thrombus. Balloon
occlusion of the aorta might be suggested to reduce the
risk. But on deflating the balloon, potential thrombus
material would be lost, casting doubt on its efficacy. Filter
systems (eg, temporary caval filters) are not appropriate for
the aorta. We recommend that visceral and peripheral an-
giography should be routinely used at the end of the
procedure to detect potential embolic events caused by the
intervention so they can be treated simultaneously.
CONCLUSION
Mobile thrombus of the thoracic aorta is a rare pathol-
ogy that lacks a standardized therapeutic approach and, sofar, lacks comparative studies. We describe the successful
primary treatment of a symptomatic mobile thrombus in
the thoracic aorta by stent graft. This case shows that ESG
treatment is an effective, minimally invasive treatment of
symptomatic mobile thoracic aortic thrombus.
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